ONCAlert | 2017 San Antonio Breast Cancer Symposium

Dr. Chan Discusses Cabozantinib for the Treatment of NETs

Jennifer Chan MD, MPH
Published Online:10:55 AM, Wed November 1, 2017

Jennifer Chan, MD, MPH, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, discusses a study exploring cabozantinib (Cabometyx) for the treatment of patients with advanced carcinoid and pancreatic neuroendocrine tumors.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.